3rd Jun 2015 07:00
3 June 2015
Sphere Medical Holding plc
Board Change
Cambridge, UK, 3 June 2015: Sphere Medical Holding plc (AIM: SPHR.L), ("Sphere Medical" or the "Company") a leading provider of innovative monitoring and diagnostic devices for the critical care setting, announces that on 3 June 2015 Matthew Hall, Chief Financial Officer, has given notice of his intention to leave the Company at the conclusion of the Company's Annual General Meeting on 25 June 2015 in order to pursue other business interests. Matthew will remain as a Consultant to the Company for a period of time in order to ensure a smooth transition and a search to appoint a new Chief Financial Officer is underway.
Dr. Anthony Martin, Non-Executive Chairman of Sphere Medical, said: "The Board would like to thank Matthew for his considerable contribution to the Company over the past four years. Matthew joined Sphere Medical prior to its IPO in November 2011 and since then has played a significant role in the continued development of the Company. He was instrumental in concluding the collaboration agreement with Ortho-Clinical Diagnostics in July 2013 and the associated equity fundraising. More recently Matthew has been a key part of the executive management team led by Wolfgang Rencken, which has orientated the business towards commercialisation of Proxima and earlier this year he was also integral to the £13.2 million placing and open offer which has provided the Company with the funds necessary to deliver near-term operational and commercial value drivers. We wish him continued success in his future career."
Matthew Hall said: "I leave the Company with Proxima 3 being commercialised in the UK and Europe, the development of Proxima 4 nearing completion and a strong balance sheet to enable the Company to achieve its near-term milestones. I firmly believe that Proxima has considerable potential in the intensive and critical care setting."
For further information, please contact:
Sphere Medical Holding plc | Tel: +44 (0)1223 875 222 | |
Dr Wolfgang Rencken, Chief Executive Officer | ||
Matthew Hall, Chief Financial Officer | ||
Peel Hunt LLP | Tel: +44 (0) 20 7418 8900 | |
James Steel | ||
Oliver Jackson | ||
Jock Maxwell Macdonald | ||
finnCap | Tel: +44 (0) 20 7220 0500 | |
Geoff Nash / Simon Hicks | ||
Stephen Norcross | ||
Consilium Strategic Communications | Tel: +44 (0) 20 3709 5700 | |
Mary-Jane Elliott | ||
Ivar Milligan | ||
Matthew Neal | ||
Notes for Editors
About Sphere Medical (AIM: SPHR.L)
Sphere Medical is a medical device company developing and commercialising a range of innovative monitoring and diagnostic devices designed to significantly improve patient care.
Sphere Medical's vision is to become a leading solution provider to the critical care market offering innovative, near real time, point of care diagnostic and monitoring products to enable closer control of therapeutic response and improve patient outcomes and reduce the overall cost of care.
The Company's strategy is focused on developing the Proxima (CE marked device) platform for measuring blood gases, electrolytes and metabolites. The Company is already marketing its Proxima product directly to the critical care market, which includes the ICU and OR, with a dedicated field sales force in the UK, Germany, the Netherlands and Belgium. The Company also proposes to work with partners for the worldwide distribution of Proxima.
Proxima delivers near real time analysis of blood gases and electrolytes metabolites, at the patient's bedside. Proxima can be used on patients across a wide therapeutic range, enabling faster clinical decision making and improved patient outcomes, whilst potentially reducing costs for healthcare payers.
Sphere Medical entered into a collaboration agreement with Ortho-Clinical Diagnostics (now part of Carlyle Group) in 2013 for the development of Proxima and enhancement of Sphere Medical's operational and production capabilities.
For further information, please visit www.spheremedical.com
Related Shares:
Sphere Medical Holding